A Beautiful Mind: John Nash, Schizophrenia, Game Theory and Recovery from Schizophrenia With and Without Medication

Tuesday, October 18, 2016
A Beautiful Mind: John Nash, Schizophrenia, Game Theory and Recovery from Schizophrenia With and Without Medication

This webinar will discuss the possible role of prodromal schizophrenia in shaping the seminal contributions of the late John Nash to game theory and how his son’s struggle with schizophrenia motivated Nash to seek and achieve partial functional recovery, while not taking antipsychotic medication. The presentation will also address novel medications for schizophrenia and current pharmacogenetics research to guide choice of medications which could enable better outcomes in schizophrenia, and recovery from chronic severe psychosis and cognitive impairment in an exceptional patient who challenges current widely held beliefs about the mood disorder-schizophrenia spectrum.

Watch Video Recording:

Presented by 
Herbert Y. Meltzer, M.D. discovers clozapine works for treatment-resistant schizophrenia patients and to help reduce suicide
Herbert Y. Meltzer, M.D.
Northwestern University Feinberg School of Medicine

Professor of Psychiatry and Behavioral Sciences and of Physiology

Scientific Council Member (Founding Member)

2007, 2000, 1994, 1988 Distinguished Investigator Grant

1992 Lieber Prizewinner for Outstanding Achievement in Schizophrenia Research

Dr. Meltzer directs a multifaceted research program in schizophrenia and bipolar disorder which is devoted to developing more effective treatments. He is one of a few clinical researchers also heavily engaged in basic research. He is particularly renowned for having been the principal investigator of the seminal trials that led to the approval of clozapine for treatment-resistant schizophrenia (1988) and patients who are at high risk for suicide (2003). He also is credited with articulating the theory that atypical antipsychotics such as clozapine owe much of their advantage over typical drugs to the balance between serotonin and dopamine receptor blockade (1989). Dr. Meltzer is an active clinician who directs the clinical trial research effort at mental health centers in Chicago and Cleveland.

Prior to joining Northwestern, Dr. Meltzer taught at Vanderbilt University, where he also directed the psychosis program.

Moderated by 
Jeffrey Borenstein, M.D.
Brain & Behavior Research Foundation

President and CEO

Jeffrey Borenstein, M.D., serves as the President & CEO of the Brain & Behavior Research Foundation, the largest private funder of mental health research grants. Dr. Borenstein developed the Emmy Award-nominated public television program “Healthy Minds,” and serves as host of the series. The program, which is broadcast nationwide, focuses on topics in psychiatry in order to educate the public, reduce stigma and offer a message of hope. Dr. Borenstein also serves as Editor-in-Chief of Psychiatric News, the newspaper of the American Psychiatric Association and as an Associate Clinical Professor of Psychiatry at Columbia University College of Physicians and Surgeons.